Single-Domain Antibody-Based Protein Degrader for Synucleinopathies
Yixiang Jiang(New York University), Einar M. Sigurdsson(New York University)
Cited by 3
Related Papers
Tau-targeting therapies for Alzheimer disease: current status and future directions
|Nature Reviews Neurology|2023|309
Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology
|Science Advances|2023|36
Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging
|EBioMedicine|2018|35
Single-domain antibody-based protein degrader for synucleinopathies
|Molecular Neurodegeneration|2024|12
Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects
|Cell Death and Disease|2024|7